Flexible-Dose Trial in Early Parkinson's Disease (PD)
Public ClinicalTrials.gov record NCT04223193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Study identification
- NCT ID
- NCT04223193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 304 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 6, 2020 (Actual)
- Primary completion
- Oct 1, 2024 (Actual)
- Completion
- Oct 1, 2024 (Actual)
- Last update posted
- Nov 21, 2025
2020 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 9
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fresno, California | Fresno | California | 93710 | — |
| Boca Raton, Florida | Boca Raton | Florida | 33487 | — |
| Maitland, Florida | Maitland | Florida | 32751 | — |
| Ocala, Florida | Ocala | Florida | 34470 | — |
| Winter Park, Florida | Winter Park | Florida | 32792 | — |
| Boston Neuro Research Center | North Dartmouth | Massachusetts | 02747 | — |
| Albany, New York | Albany | New York | 12208 | — |
| Syracuse, New York | Syracuse | New York | 13210 | — |
| Cincinnati, Ohio | Cincinnati | Ohio | 45212 | — |
| Cleveland, Ohio | Cleveland | Ohio | 44195 | — |
| Memphis, Tennessee | Memphis | Tennessee | 38157 | — |
| Cypress, Texas | Cypress | Texas | 77429 | — |
| Houston, Texas | Houston | Texas | 77030 | — |
| Lubbock, Texas | Lubbock | Texas | 79410 | — |
| Round Rock, Texas | Round Rock | Texas | 78681 | — |
| Richmond, Virginia | Richmond | Virginia | 23229 | — |
| Richmond, Virginia | Richmond | Virginia | 23233 | — |
| Kirkland, Washington | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04223193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04223193 live on ClinicalTrials.gov.